Nama's AI scorecard currently rates Zai Lab Sell (3.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does ZLAB report earnings?

Zai Lab's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.59.

What is the ZLAB price target?

The median analyst price target from 12 analysts is $33.85, with a range of $24.25 – $50.00.

Is ZLAB Shariah compliant?

Nama's AAOIFI-style screen reads Zai Lab as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Zai Lab (ZLAB)

Healthcare · Biotechnology · NASDAQ

Zai Lab (ZLAB) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $3.16B and a free-cash-flow yield of -5.9%. Over the most recent reported fiscal year, revenue grew 15.3%. Nama's AI scorecard rates it Sell, 3.9 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 3.9/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Middle · +9.3% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-72.3%

How far the last close sits under the highest price of the past five years.

Market cap	$3.16B
Trailing P/E	—
Price / book	47.2
Price / sales	7.0
FCF yield	-5.9%
Dividend yield	—
Gross margin	56.5%
Operating margin	-58.3%
Net margin	-41.9%
Revenue growth (YoY)	+15.3%
Revenue growth (3-yr annual)	+28.9%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.7
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

ZLAB earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate -$0.59). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	-$0.41	-$0.59	+30.5%	$108.21M
Q2 2026	Aug 6, 2026	-$0.46	-$0.68	+32.4%	$106.31M
Q1 2026	May 7, 2026	-$0.46	-$0.53	+13.2%	$99.61M
Q4 2025	Feb 26, 2026	-$0.46	-$0.42	-9.5%	$127.60M

ZLAB analyst price target

Median target $33.85 from 12 analysts, ranging $24.25 – $50.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live ZLAB data on Nama Insights →

ZLAB FAQ

Is ZLAB a buy?: Nama's AI scorecard currently rates Zai Lab Sell (3.9 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does ZLAB report earnings?: Zai Lab's next scheduled report is on Feb 25, 2027. Analysts expect EPS of -$0.59.
What is the ZLAB price target?: The median analyst price target from 12 analysts is $33.85, with a range of $24.25 – $50.00.
Is ZLAB Shariah compliant?: Nama's AAOIFI-style screen reads Zai Lab as Not Shariah Compliant. At least one of the three ratios or the industry test failed.